Malignant pleural mesothelioma: Surgical roles and novel therapies

Clinical Lung Cancer

Volumn 3, Issue 2, 2001, Pages 102-117

  Pass, H I ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

Brachytherapy; Extrapleural pneumonectomy; Intrapleural chemotherapy; Multimodality treatment; Photodynamic therapy

Indexed keywords

3 [(4,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; ANTHRACYCLINE DERIVATIVE; ANTIMETABOLITE; CARBOPLATIN; CHEMOKINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; GAMMA INTERFERON; GEMCITABINE; INTERFERON; INTERLEUKIN 2; METHOTREXATE; MITOMYCIN C; NAVELBINE; PACLITAXEL; PEMETREXED; PHOTOFRIN II; PLATINUM DERIVATIVE; RALTITREXED; RANPIRNASE; RIBONUCLEASE; TAMOXIFEN; UNCLASSIFIED DRUG; VASCULOTROPIN; VINDESINE;

CANCER IMMUNOTHERAPY; CANCER RESEARCH; CANCER SURVIVAL; CANCER THERAPY; CLINICAL FEATURE; CLINICAL PROTOCOL; CONSULTATION; CONTROLLED STUDY; FATALITY; FINANCIAL MANAGEMENT; GENE THERAPY; HUMAN; HUMAN TISSUE; HYPERTHERMIC THERAPY; INTRAOPERATIVE PERIOD; LUNG RESECTION; MALIGNANT MESOTHELIOMA; PHOTODYNAMIC THERAPY; PLEURA MESOTHELIOMA; PLEURECTOMY; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0035208024     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2001.n.021     Document Type: Review

References (111)

1. The European mesothelioma epidemic
2. Diffuse malignant mesothelioma. Prospective evaluation of 69 patients
3. Benign and malignant mesothelioma
4. Malignant mesothelioma 1982: Review of 4710 published cases
5. Asbestos and mesothelioma: A review
6. Diagnosis and treatment of pleural mesothelioma
7. Diffuse malignant pleural mesothelioma in Glasgow
8. Thrombocytosis in malignant pleural mesothelioma
9. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B
10. Computed tomography of localized pleural mesothelioma
11. Computed tomography of asbestos-related pulmonary parenchymal and pleural diseases
12. Computed tomography in the diagnosis of asbestos-related thoracic disease
13. Computed tomography in mesothelioma
14. The role of computed tomography scanning in the initial assessment and the follow-up of malignant pleural mesothelioma
15. Correlations between findings at computed tomography (CT) and at thoracoscopy/thoracotomy/autopsy in pleural mesothelioma
16. Malignant pleural mesothelioma: Value of CT and MR imaging in predicting resectability
17. Prognostic value of FDG PET imaging in malignant pleural mesothelioma
18. Malignant mesothelioma of the pleura: Relation between histological type and clinical behaviour
19. Early diagnosis of malignant mesothelioma: The contribution of effusion and fine needle aspiration cytology and ancillary techniques
20. Pleural biopsy in the diagnosis of malignant mesothelioma
21. Malignant pleural diseases
22. Thoracoscopy in undiagnosed pleural effusions
23. Medical thoracoscopy, results and complications in 146 patients: A retrospective study
24. Laparoscopy: An important tool in the staging of malignant pleural mesothelioma
25. The influence of the diagnostic technique on the histopathological diagnosis in malignant mesothelioma
26. Intracranial metastases from malignant pleural mesothelioma. Report of three autopsy cases and review of the literature
27. Metastases in diffuse pleural mesothelioma: Influence of histological type
28. Sarcomatous pleural mesothelioma and cerebral metastases: Case report and a review of eight cases
29. Current pathogenetic concepts of diffuse malignant mesothelioma
30. Diagnosis of malignant pleural mesothelioma by axillary lymph node biopsy
31. Extrathoracic lymph node metastases in malignant pleural mesothelioma
32. Malignant pleural mesothelioma
33. Thoracoscopic talc poudrage pleurodesis for malignant effusions. A review of 360 cases
34. Videothoracoscopy in the diagnosis and treatment of malignant pleural mesothelioma with associated pleural effusions
35. [Value of thoracoscopy and talc pleurodesis in diagnosis and palliative treatment of malignant pleural mesothelioma]
36. Use of an implantable pleural catheter for trapped lung syndrome in patients with malignant pleural effusion
37. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group
38. The importance of surgical staging in the treatment of malignant pleural mesothelioma
39. Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma
40. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: Results in 183 patients
41. The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial
42. Pleurectomy/decortication in the setting of multimodality treatment for diffuse malignant pleural mesothelioma
43. The treatment of malignant pleural effusions by partial pleurectomy
44. Pleurectomy in the treatment of pleural effusion due to metastatic malignancy
45. Surgically debulked malignant pleural mesothelioma: Results and prognostic factors
46. Malignant mesothelioma of the pleura: A study of 52 treated and 64 untreated patients
47. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: A retrospective study of 332 patients
48. Pleurectomy for mesothelioma
49. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients
50. 1986: Extrapleural pneumonectomy for diffuse, malignant mesothelioma. Updated in 1994
51. Patterns of failure after trimodality therapy for malignant pleural mesothelioma
52. Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically
53. A phase II trial of surgical resection and high-dose hemithoracic radiation for malignant pleural mesothelioma
54. A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma
55. Aggressive combined modality treatment for malignant mesothelioma
56. Surgery followed by intracavitary plus systemic chemotherapy in malignant pleural mesothelioma
57. Malignant mesothelioma of the pleura. A prospective therapeutic study of 132 patients from 1981-1985
58. Use of photodynamic therapy for the management of pleural malignancies
59. Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma
60. Photodynamic therapy of pleural mesothelioma
61. Photodynamic therapy as adjuvant therapy in surgically treated pleural malignancies
62. Experiences of photodynamic therapy in dermatology
63. Operation and photodynamic therapy for pleural mesothelioma: 6-year follow-up
64. Malignant pleural mesothelioma (MPM) treatment with extrapleural pneumonectomy (EPP) and intra-operative photodynamic therapy (iPDT) using mTHPC as photosensitiser: Long term outcome and toxicity
65. Malignant mesothelioma. The Eastern Cooperative Oncology Group (ECOG) experience
66. High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study
67. Cisplatin and gemcitabine treatment for malignant mesothelioma: A phase II study
68. Carboplatin and gemcitabine chemotherapy for malignant pleural mesothelioma: A phase II study of the GSTPV
69. High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234
70. Docetaxel for malignant mesothelioma: Phase II study of the Eastern Cooperative Oncology Group (ECOG 2595)
71. Phase II study of vinorelbine in patients with malignant pleural mesothelioma
72. Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma
73. Malignant Pleural Mesothelioma
74. Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin
75. Alimta in combination with carboplatin demonstrates clinical activity against malignant mesothelioma in a phase I trial
76. Phase II trial of Onconase® (ONC) in patients (pts) with advanced malignant mesothelioma (MM): Analysis of survival
77. Phase III randomized trial of onconase (ONC) vs. doxorubicin (DOX) in patients (pts) with unresectable malignant mesothelioma (UMM): Analysis of survival
78. Combination raltitrexed (Tomudex (R))-oxaliplatin: A step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma
79. Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally in patients (pts) with malignant pleural mesothelioma (MPM)
80. Pleural space perfusion with cisplatin in the multimodality treatment of malignant mesothelioma: A feasibility and pharmacokinetic study
81. Management of peritoneal-surface malignancy: The surgeon's role
82. Continuous hyperthermic peritoneal perfusion with cisplatin for the treatment of peritoneal mesothelioma
83. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: Results of a phase I clinical trial in malignant mesothelioma
84. Cationic lipid: Bacterial DNA complexes elicit adaptive cellular immunity in murine intraperitoneal tumor models
85. Evaluation of an E1E4-deleted adenovirus expressing the herpes simplex thymidine kinase suicide gene in cancer gene therapy
86. The treatment of malignant mesothelioma with a gene modified cancer cell line: A phase I study
87. Gene therapy for malignant mesothelioma: A novel approach for an incurable cancer with increased incidence in Louisiana
88. Antitumor activity with the HSV-tk-gene-modified cell line PA-1-STK in malignant mesothelioma
89. Adenovirus-mediated p14(ARF) gene transfer in human mesothelioma cells
90. Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma
91. Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: A phase II study
92. SV40 induces mesotheliomas in hamsters
93. SV40 large T-antigen and human pleural mesothelioma. Screening by polymerase chain reaction and tyramine-amplified immunohistochemistry
94. SV40 expression in human neoplastic and non-neoplastic tissues: Perspectives on diagnosis, prognosis and therapy of human malignant mesothelioma
95. SV40-like DNA sequences in pleural mesothelioma, bronchopulmonary carcinoma, and non-malignant pulmonary diseases
96. Detection of SV40 sequences in human mesothelioma
97. SV40 DNA sequences in mesotheliomas
98. Simian virus 40 large T antigen (SV40LTAg) primer specific DNA amplification in human pleural mesothelioma tissue
99. Molecular biology studies on mesothelioma tumor samples: Preliminary data on H-ras, p21, and SV40
100. A multi-institutional study confirms the presence and expression of simian virus 40 in human malignant mesotheliomas
101. The retinoblastoma gene family pRb/p105, p107, pRb2/p130 and simian virus-40 large T-antigen in human mesotheliomas
102. Simian virus-40 large-T antigen binds p53 in human mesotheliomas
103. Cancer risk associated with simian virus 40 contaminated polio vaccine
104. Potential exposure to SV40 in polio vaccines used in Sweden during 1957: No impact on cancer incidence rates 1960 to 1993
105. Contamination of poliovirus vaccines with simian virus 40 (1955-1963) and subsequent cancer rates
106. [Epidemiological approach to mesothelioma]
107. Immunotherapy of SV40 induced tumours in mice: A model for vaccine development
108. Induction of tumor antigen-specific immunity in vivo by a novel vaccinia vector encoding safety-modified simian virus 40 T antigen
109. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours
110. Prognostic factors for malignant mesothelioma in 142 patients: Validation of CALGB and EORTC prognostic scoring systems
111. Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study